- Home
- GCTS vs SKYE Comparison
GCTS vs SKYE Comparison
Compare GCTS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- SKYE
- Stock Information
- Founded
- GCTS 1998
- SKYE 2012
- Country
- GCTS United States
- SKYE United States
- Employees
- GCTS N/A
- SKYE N/A
- Industry
- GCTS Blank Checks
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- GCTS Finance
- SKYE Health Care
- Exchange
- GCTS Nasdaq
- SKYE Nasdaq
- Market Cap
- GCTS 91.7M
- SKYE 80.7M
- IPO Year
- GCTS N/A
- SKYE N/A
- Fundamental
- Price
- GCTS $1.45
- SKYE $1.44
- Analyst Decision
- GCTS Strong Buy
- SKYE Buy
- Analyst Count
- GCTS 1
- SKYE 6
- Target Price
- GCTS $5.00
- SKYE $16.60
- AVG Volume (30 Days)
- GCTS 220.2K
- SKYE 1.7M
- Earning Date
- GCTS 05-13-2025
- SKYE 05-09-2025
- Dividend Yield
- GCTS N/A
- SKYE N/A
- EPS Growth
- GCTS N/A
- SKYE N/A
- EPS
- GCTS N/A
- SKYE N/A
- Revenue
- GCTS $9,128,000.00
- SKYE N/A
- Revenue This Year
- GCTS $315.69
- SKYE N/A
- Revenue Next Year
- GCTS $170.56
- SKYE N/A
- P/E Ratio
- GCTS N/A
- SKYE N/A
- Revenue Growth
- GCTS N/A
- SKYE N/A
- 52 Week Low
- GCTS $1.16
- SKYE $1.14
- 52 Week High
- GCTS $7.00
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- GCTS 41.08
- SKYE 40.43
- Support Level
- GCTS $1.37
- SKYE $1.26
- Resistance Level
- GCTS $1.57
- SKYE $3.73
- Average True Range (ATR)
- GCTS 0.16
- SKYE 0.34
- MACD
- GCTS 0.01
- SKYE 0.04
- Stochastic Oscillator
- GCTS 41.84
- SKYE 11.40
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc. is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.